Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partnrs
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports. Several other brokerages also recently commented on FULC. Cantor Fitzgerald raised Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 […]
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports. Several other brokerages also recently commented on FULC. Cantor Fitzgerald raised Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 […]
